The scientist’s investigation covers issues in Psychiatry, Attention deficit hyperactivity disorder, Clinical psychology, Methylphenidate and Developmental psychology. The concepts of his Psychiatry study are interwoven with issues in Young adult, Clinical trial and Pediatrics. His Attention deficit hyperactivity disorder research is multidisciplinary, incorporating elements of Neurofeedback, Placebo, Randomized controlled trial and Stimulant.
His studies in Clinical psychology integrate themes in fields like Juvenile delinquency and Substance abuse. His Methylphenidate research integrates issues from Borderline intellectual functioning, Regimen, Parent training, Cognitive test and Pervasive developmental disorder. His work on Aggression, Rejection and Child development as part of general Developmental psychology research is often related to Social environment, thus linking different fields of science.
L. Eugene Arnold mainly investigates Psychiatry, Clinical psychology, Attention deficit hyperactivity disorder, Randomized controlled trial and Autism. His research brings together the fields of Pediatrics and Psychiatry. His Clinical psychology research incorporates elements of Developmental psychology, Aggression, Parent training and Depression.
In the field of Attention deficit hyperactivity disorder, his study on Methylphenidate overlaps with subjects such as Multimodal treatment. L. Eugene Arnold has researched Randomized controlled trial in several fields, including Placebo and Clinical trial. L. Eugene Arnold works mostly in the field of Autism, limiting it down to topics relating to Risperidone and, in certain cases, Weight gain, as a part of the same area of interest.
His primary areas of study are Clinical psychology, Psychiatry, Attention deficit hyperactivity disorder, Randomized controlled trial and Placebo. He interconnects Bipolar disorder, Depression, Parent training and Aggression in the investigation of issues within Clinical psychology. His Psychiatry research includes elements of Young adult and Epidemiology.
The Attention deficit hyperactivity disorder study combines topics in areas such as Developmental psychology and Pediatrics. His work in Randomized controlled trial tackles topics such as Mood disorders which are related to areas like Psychological intervention. His study in Placebo is interdisciplinary in nature, drawing from both Internal medicine, Clinical trial, Autism, Autism spectrum disorder and Physical therapy.
His primary scientific interests are in Clinical psychology, Psychiatry, Placebo, Randomized controlled trial and Attention deficit hyperactivity disorder. He combines subjects such as Bipolar disorder, Suspected autism and Comorbidity with his study of Clinical psychology. His work deals with themes such as Young adult and Cohort, which intersect with Psychiatry.
His Placebo study combines topics in areas such as Internal medicine, Autism, Autism spectrum disorder, Randomization and Depression. His Randomized controlled trial study integrates concerns from other disciplines, such as Physical therapy, Parent training, Mood disorders and Impulsivity. His studies deal with areas such as Developmental psychology, Amygdala and Circadian rhythm as well as Attention deficit hyperactivity disorder.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity
David J. Posey;David J. Posey;Michael G. Aman;L. Eugene Arnold;Yaser Ramadan.
Archives of General Psychiatry (2005)
Which treatment for whom for ADHD? Moderators of treatment response in the MTA
Elizabeth B. Owens;Stephen P. Hinshaw;Helen C. Kraemer;L. Eugene Arnold.
Journal of Consulting and Clinical Psychology (2003)
National Institute of Mental Health Collaborative Multimodal Treatment Study of Children With ADHD (the MTA): Design Challenges and Choices
L. Eugene Arnold;Howard B. Abikoff;Dennis P. Cantwell;C. Keith Conners.
Archives of General Psychiatry (1997)
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
L. Eugene Arnold;Michael G. Aman;Amelia M. Cook;Andrea N. Witwer.
Journal of the American Academy of Child and Adolescent Psychiatry (2006)
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects
Brooke S.G. Molina;Kate Flory;Stephen P. Hinshaw;Andrew R. Greiner.
Journal of the American Academy of Child and Adolescent Psychiatry (2007)
Peer rejection and friendships in children with Attention-Deficit/Hyperactivity Disorder: contributions to long-term outcomes.
Sylvie Mrug;Brooke S. G. Molina;Betsy Hoza;Alyson C. Gerdes.
Journal of Abnormal Child Psychology (2012)
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary.
James Swanson;L. Eugene Arnold;Helena Kraemer;Lily Hechtman.
Journal of Attention Disorders (2008)
Gastrointestinal Symptoms in a Sample of Children with Pervasive Developmental Disorders
Roumen N. Nikolov;Karen E. Bearss;Jelle Lettinga;Craig Erickson.
Journal of Autism and Developmental Disorders (2009)
Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 Months
Michael G. Aman;L. Eugene Arnold;Ronald Lindsay;Patricia Nash.
A Review of Neurofeedback Treatment for Pediatric ADHD
Nicholas Lofthouse;L. Eugene Arnold;Sarah Hersch;Elizabeth Hurt.
Journal of Attention Disorders (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: